These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24756015)

  • 1. Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis.
    Tabibian JH; Enders F; Imam MH; Kolar G; Lindor KD; Talwalkar JA
    Ann Hepatol; 2014; 13(3):384-9. PubMed ID: 24756015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study.
    Chalasani N; Baluyut A; Ismail A; Zaman A; Sood G; Ghalib R; McCashland TM; Reddy KR; Zervos X; Anbari MA; Hoen H
    Hepatology; 2000 Jan; 31(1):7-11. PubMed ID: 10613720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience.
    Goss JA; Shackleton CR; Farmer DG; Arnaout WS; Seu P; Markowitz JS; Martin P; Stribling RJ; Goldstein LI; Busuttil RW
    Ann Surg; 1997 May; 225(5):472-81; discussion 481-3. PubMed ID: 9193175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of Inflammatory Bowel Disease Is Associated With Increased Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis and IBD.
    Gulamhusein AF; Eaton JE; Tabibian JH; Atkinson EJ; Juran BD; Lazaridis KN
    Am J Gastroenterol; 2016 May; 111(5):705-11. PubMed ID: 27002801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening and diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.
    Jesudian AB; Jacobson IM
    Rev Gastroenterol Disord; 2009; 9(2):E41-7. PubMed ID: 19668124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.
    Burak K; Angulo P; Pasha TM; Egan K; Petz J; Lindor KD
    Am J Gastroenterol; 2004 Mar; 99(3):523-6. PubMed ID: 15056096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR4, TLR9, and NLRP3 in biliary epithelial cells of primary sclerosing cholangitis: relationship with clinical characteristics.
    Matsushita H; Miyake Y; Takaki A; Yasunaka T; Koike K; Ikeda F; Shiraha H; Nouso K; Yamamoto K
    J Gastroenterol Hepatol; 2015 Mar; 30(3):600-8. PubMed ID: 25160604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of primary sclerosing cholangitis.
    Björnsson E
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):163-72. PubMed ID: 19305376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis.
    Saffioti F; Roccarina D; Vesterhus M; Hov JR; Rosenberg W; Pinzani M; Pereira SP; Boberg KM; Thorburn D
    Eur J Clin Invest; 2019 May; 49(5):e13088. PubMed ID: 30762236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
    Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
    Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting cholangiocarcinoma in primary sclerosing cholangitis: using artificial intelligence, clinical and laboratory data.
    Hu C; Iyer RK; Juran BD; McCauley BM; Atkinson EJ; Eaton JE; Ali AH; Lazaridis KN
    BMC Gastroenterol; 2023 Apr; 23(1):129. PubMed ID: 37076803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma.
    Boyd S; Mustonen H; Tenca A; Jokelainen K; Arola J; Färkkilä MA
    Scand J Gastroenterol; 2017 Feb; 52(2):242-249. PubMed ID: 27806633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.
    Lapitz A; Azkargorta M; Milkiewicz P; Olaizola P; Zhuravleva E; Grimsrud MM; Schramm C; Arbelaiz A; O'Rourke CJ; La Casta A; Milkiewicz M; Pastor T; Vesterhus M; Jimenez-Agüero R; Dill MT; Lamarca A; Valle JW; Macias RIR; Izquierdo-Sanchez L; Pérez Castaño Y; Caballero-Camino FJ; Riaño I; Krawczyk M; Ibarra C; Bustamante J; Nova-Camacho LM; Falcon-Perez JM; Elortza F; Perugorria MJ; Andersen JB; Bujanda L; Karlsen TH; Folseraas T; Rodrigues PM; Banales JM
    J Hepatol; 2023 Jul; 79(1):93-108. PubMed ID: 36868481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience.
    Kuzu UB; Ödemiş B; Suna N; Yıldız H; Parlak E; Dişibeyaz S; Torun S; Akpınar MY; Coşkun O; Turhan N; Yüksel M; Kayaçetin E
    J Gastrointest Cancer; 2016 Mar; 47(1):8-14. PubMed ID: 26537791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis.
    Benito de Valle M; Müller T; Björnsson E; Otten M; Volkmann M; Guckelberger O; Wiedenmann B; Sadik R; Schott E; Andersson M; Berg T; Lindkvist B
    Dig Liver Dis; 2014 Oct; 46(10):903-8. PubMed ID: 25091876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology and outcomes of primary sclerosing cholangitis: an Australian multicentre retrospective cohort study.
    Tan N; Ngu N; Worland T; Lee T; Abrahams T; Pandya K; Freeman E; Hannah N; Gazelakis K; Madden RG; Lynch KD; Valaydon Z; Sood S; Dev A; Bell S; Thompson A; Ding J; Nicoll AJ; Liu K; Gow P; Lubel J; Kemp W; Roberts SK; Majeed A;
    Hepatol Int; 2022 Oct; 16(5):1094-1104. PubMed ID: 35657479
    [TBL] [Abstract][Full Text] [Related]  

  • 17.  Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis.
    Hilscher M; Enders FB; Carey EJ; Lindor KD; Tabibian JH
    Ann Hepatol; 2016; 15(2):246-53. PubMed ID: 26845602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.
    Weismüller TJ; Trivedi PJ; Bergquist A; Imam M; Lenzen H; Ponsioen CY; Holm K; Gotthardt D; Färkkilä MA; Marschall HU; Thorburn D; Weersma RK; Fevery J; Mueller T; Chazouillères O; Schulze K; Lazaridis KN; Almer S; Pereira SP; Levy C; Mason A; Naess S; Bowlus CL; Floreani A; Halilbasic E; Yimam KK; Milkiewicz P; Beuers U; Huynh DK; Pares A; Manser CN; Dalekos GN; Eksteen B; Invernizzi P; Berg CP; Kirchner GI; Sarrazin C; Zimmer V; Fabris L; Braun F; Marzioni M; Juran BD; Said K; Rupp C; Jokelainen K; Benito de Valle M; Saffioti F; Cheung A; Trauner M; Schramm C; Chapman RW; Karlsen TH; Schrumpf E; Strassburg CP; Manns MP; Lindor KD; Hirschfield GM; Hansen BE; Boberg KM;
    Gastroenterology; 2017 Jun; 152(8):1975-1984.e8. PubMed ID: 28274849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholangiocytes in the pathogenesis of primary sclerosing cholangitis and development of cholangiocarcinoma.
    Chung BK; Karlsen TH; Folseraas T
    Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1390-1400. PubMed ID: 28844951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis.
    Villard C; Friis-Liby I; Rorsman F; Said K; Warnqvist A; Cornillet M; Kechagias S; Nyhlin N; Werner M; Janczewska I; Hagström T; Nilsson E; Bergquist A
    J Hepatol; 2023 Mar; 78(3):604-613. PubMed ID: 36410555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.